A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/ecp.13.18PMID 23656339PMCID PMC4198941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy

  2015cited by this paper
• In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor

  2013cited by this paper
• CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction

  2013cited by this paper
• Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study

  2013cited by this paper
• Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan

  2012cited by this paper
• Global burden of hepatitis C: considerations for healthcare providers in the United States.

  2012cited by this paper
• Lack of Indinavir Effects on Methadone Disposition Despite Inhibition of Hepatic and Intestinal Cytochrome P4503A (CYP3A)

  2012cited by this paper
• Effect of Telaprevir on the Pharmacokinetics of Buprenorphine in Volunteers on Stable Buprenorphine/Naloxone Maintenance Therapy

  2012cited by this paper
• HIV prevalence and risk behaviours among injecting drug users in six indonesian cities implications for future HIV prevention programs

  2012cited by this paper
• P-Glycoprotein Is a Major Determinant of Norbuprenorphine Brain Exposure and Antinociception

  2012cited by this paper
• Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication

  2012cited by this paper
• Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers.

  2012cited by this paper
• Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and Pharmacodynamics

  2012cited by this paper
• Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.

  2012cited by this paper
• Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.

  2012influential reference
• Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood–brain barrier in mice

  2012cited by this paper
• Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al.

  2011cited by this paper
• Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.

  2011cited by this paper
• Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor

  2011cited by this paper
• Integration of buprenorphine for substance-abuse treatment by HIV care providers.

  2011cited by this paper
• Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence

  2011cited by this paper
• CYP2B6 and OPRM1 gene variations predict methadone‐related deaths

  2011cited by this paper
• Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and Response

  2011cited by this paper
• Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone

  2011cited by this paper
• Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

  2011cited by this paper
• CYP2B6 Polymorphisms Influence the Plasma Concentration and Clearance of the Methadone S-Enantiomer

  2011cited by this paper
• Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients

  2011cited by this paper
• Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

  2011cited by this paper
• Prevention of HIV-1 infection with early antiretroviral therapy

  2011cited by this paper
• Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

  2011cited by this paper
• Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.

  2011cited by this paper
• Pharmacokinetic Interactions Between Darunavir/Ritonavir and Opioid Maintenance Therapy Using Methadone or Buprenorphine/Naloxone

  2011cited by this paper
• Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir

  2011cited by this paper
• HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study

  2011cited by this paper
• Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings.

  2010influential reference
• Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir

  2010influential reference
• Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

  2010cited by this paper
• Effect of Raltegravir on the Pharmacokinetics of Methadone

  2010cited by this paper
• Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone

  2010cited by this paper
• Methadone: A Substrate and Mechanism-Based Inhibitor of CYP19 (Aromatase)

  2010cited by this paper
• Excretion and Metabolism of Lersivirine (5-{[3,5-Diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a Next-Generation Non-Nucleoside Reverse Transcriptase Inhibitor, after Administration of [14C]Lersivirine to Healthy Volunteers

  2010cited by this paper
• Drug Interactions with New and Investigational Antiretrovirals

  2010cited by this paper
• Lack of clinically significant drug interactions between nevirapine and buprenorphine.

  2010influential reference
• Contribution of the Different UDP-Glucuronosyltransferase (UGT) Isoforms to Buprenorphine and Norbuprenorphine Metabolism and Relationship with the Main UGT Polymorphisms in a Bank of Human Liver Microsomes

  2010cited by this paper
• Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.

  2010influential reference
• Pharmacokinetics and Pharmacodynamics of GS‐9350: A Novel Pharmacokinetic Enhancer Without Anti‐HIV Activity

  2010cited by this paper
• Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

  2010cited by this paper
• Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

  2010cited by this paper
• Impact of drug transporters on cellular resistance towards saquinavir and darunavir.

  2010cited by this paper
• Methadone-associated Q-T interval prolongation and torsades de pointes.

  2009cited by this paper
• Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

  2009cited by this paper
• Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases.

  2009cited by this paper
• The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.

  2009cited by this paper
• Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.

  2009cited by this paper
• Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

  2009cited by this paper
• Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

  2009cited by this paper
• Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers.

  2009cited by this paper
• Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.

  2009cited by this paper
• Drug Interactions with New and Investigational Antiretrovirals

  2009cited by this paper
• Effects of omeprazole on plasma levels of raltegravir.

  2009cited by this paper
• Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

  2008cited by this paper
• Role of CYP2B6 in Stereoselective Human Methadone Metabolism

  2008cited by this paper
• Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

  2008cited by this paper
• Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.

  2008cited by this paper
• ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence.

  2008cited by this paper
• Efavirenz Induces CYP2B6-Mediated Hydroxylation of Bupropion in Healthy Subjects

  2008cited by this paper
• The Effects of Chiral Isolates of Methadone on the Cardiac Potassium Channel IKr

  2008cited by this paper
• Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Fosamprenavir‐Ritonavir in Opioid‐Dependent Subjects

  2008cited by this paper
• Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

  2008cited by this paper
• Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: I. Evidence Against CYP3A Mediation of Methadone Clearance

  2008cited by this paper
• A Review of the Pharmacokinetics of Abacavir

  2008cited by this paper
• Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV‐Negative Volunteers

  2008cited by this paper
• Pharmacokinetic Enhancement of the Hepatitis C Virus Protease Inhibitors VX-950 and SCH 503034 by Co-Dosing with Ritonavir

  2007cited by this paper
• Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

  2007cited by this paper
• Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

  2007cited by this paper
• Stereoselective Block of hERG Channel by (S)‐Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers

  2007cited by this paper
• Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers

  2007cited by this paper
• The Effect of Multiple Doses of Peginterferon alfa‐2b on the Steady‐State Pharmacokinetics of Methadone in Patients With Chronic Hepatitis C Undergoing Methadone Maintenance Therapy

  2007cited by this paper
• Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats

  2007cited by this paper
• Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment.

  2007cited by this paper
• Clinical Pharmacokinetics of Darunavir

  2007cited by this paper
• Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda

  2007cited by this paper
• Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.

  2007cited by this paper
• Methadone Dosing Strategies in HIV-Infected Injection Drug Users Enrolled in a Directly Observed Therapy Program

  2007cited by this paper
• Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.

  2006cited by this paper
• ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment

  2006cited by this paper
• Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation.

  2006cited by this paper
• NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE

  2006cited by this paper
• Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.

  2006cited by this paper
• The In Vivo Glucuronidation of Buprenorphine and Norbuprenorphine Determined by Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry

  2006cited by this paper
• Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir.

  2006cited by this paper
• Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine.

  2006cited by this paper
• Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.

  2006cited by this paper
• Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications: Implications and Management for Clinical Practice

  2006cited by this paper
• Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action

  2006cited by this paper
• Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment

  2005cited by this paper
• Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

  2005cited by this paper
• IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS

  2005cited by this paper
• SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV

  2005cited by this paper
• Peginterferon Alfa‐2a Does Not Alter the Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy

  2005cited by this paper

• Medications to Treat Opioid Use Disorder.

  2026cites this paper
• Considerations when prescribing opioid agonist therapies for people living with HIV

  2024cites this paper
• Drug Interactions with Antiretroviral Medications

  2022cites this paper
• Factors associated with patient perceived suboptimal dosing of in-hospital opioid agonist therapy among people who use illicit drugs in Vancouver, Canada

  2022cites this paper
• Drug Interactions with Antiretroviral Medications

  2022cites this paper
• Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.

  2022cites this paper
• Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study.

  2021cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from Coronavirus Disease 2019 (COVID-19) Infection

  2020cites this paper
• Time-space constraints to HIV treatment engagement among women who use heroin in Dar es Salaam, Tanzania: A time geography perspective.

  2020cites this paper
• Physical Therapy for Chronic Pain Mitigation and Opioid Use Reduction Among People Living with Human Immunodeficiency Virus in Atlanta, GA: A Descriptive Case Series

  2020influential citation
• Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from COVID-19 Infection.

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Contemporary Drug–Drug Interactions in HIV Treatment

  2019cites this paper
• Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone

  2019cites this paper
• Methadone serum concentrations and influencing factors: A naturalistic observational study

  2019cites this paper
• Exploring Slow Release Oral Morphine (SROM) As a Transition Bridge for Medium to High Doses of Methadone Conversion to Buprenorphine/Naloxone Sublingual: A Calgary Concept and Approach

  2019cites this paper
• Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Perceived barriers to methadone maintenance treatment among Iranian opioid users

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Substance Use Disorders in People Living with Human Immunodeficiency Virus/AIDS.

  2017cites this paper
• Drug Interactions with Antiretroviral Medications

  2017influential citation
• Hepatitis C Infection among Intravenous Drug Users. “A Silent Disease in an Invisible Population”

  2017cites this paper
• Predicting drug interactions in addiction treatment

  2017cites this paper
• 2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV.

  2017cites this paper
• NOVA University of Newcastle Research Online

  2017cites this paper
• Current Concepts in Methadone Metabolism and Transport

  2017cites this paper
• Corrected QT Interval and Methadone Dose and Concentrations in Pregnant and Postpartum Women.

  2017cites this paper
• Methadone and Buprenorphine: The Place of Opiate Replacement Therapies

  2016cites this paper
• Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers

  2016cites this paper
• [The clinical relevance of drug interactions in patients with human immunodeficiency virus infection: update 2009-2014].

  2016cites this paper
• Drug interactions between buprenorphine, methadone and hepatitis C therapeutics

  2016cites this paper
• Buprenorphine – the unique opioid adjuvant in regional anesthesia

  2016cites this paper
• Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.

  2015cites this paper
• Influence of HIV antiretrovirals on methadone N-demethylation and transport.

  2015cites this paper
• Managing drug interactions in HIV-infected adults with comorbid illness

  2015cites this paper
• Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism

  2015cites this paper
• Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia.

  2015cites this paper
• Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy

  2015cites this paper
• Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.

  2015cites this paper
• DOSE-RESPONSE RELATIONSHIP BETWEEN METHADONE DOSE AND ADHERENCE TO ANTIRETROVIRAL THERAPY AMONG HIV-POSITIVE PERSONS WHO USE ILLICIT OPIOIDS

  2015cites this paper
• Drug-drug interactions: antiretroviral drugs and recreational drugs.

  2015cites this paper
• Atención clínica integral y pronóstico de pacientes con abuso de drogas e infección por el VIH

  2015cites this paper
• of Substance Abuse Treatment Treatment Readiness , Attitudes Toward , and ExperienceswithMethadone and Buprenorphine Maintenance Therapy Among People Who Inject Drugs in Malaysia

  2015cites this paper
• Differences in Methadone Metabolism by CYP2B6 Variants

  2015cites this paper
• Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.

  2015cites this paper
• The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review

  2015cites this paper
• Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug–Drug Interactions

  2015cites this paper
• Aportación al conocimiento de la farmacocinética de metadona en plasma y saliva humanos

  2014cites this paper
• Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential

  2014influential citation
• Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities.

  2013cites this paper
• Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance

  2013cites this paper
• The reply.

  2013cites this paper